PSY 627 Exam 1 Questions With
Complete Solutions
___ |administration |of |a |drug:
Via |the |GI |tract
Oral |(PO)
PO |takes |about |___-___ |hours |for |75% |of |the |does |of |most |psychoactive |drugs |to |enter |the |
blood, |depending |on |lipid |(fat) |solubility |- |CORRECT |ANSWER✔✔-Enteral
1-3
___ |administration |of |a |drug:
Avoids |the |GI |tract |and |first-pass |metabolism
Inhaled
Transmucosal
Intravenous |(IV)
Intramuscular |(IM)
Transdermal |- |CORRECT |ANSWER✔✔-Parenteral
Rapid |vs. |Slow |Metabolizers:
A |second |drug |may |affect |the |metabolism |of |a |first |drug |(effect |genes/protein) |changes |
plasma/blood |level |of |the |active |(un-metabolized) |form |of |the |second |drug. |
, ___ |plasma |level |→ |SE's/toxicity. |
___ |in |plasma |level |→ |decrease |effectiveness. |- |CORRECT |ANSWER✔✔-Increase
Decrease
"Rule |of |Thumb" |for |Elderly |Doses
The |dose |is |usually |decreased |by |___%* |because:
-Decreased |hepatic |(live) |or |renal |(kidney) |function |may |cause |___ |levels
-Less |effective |barriers |to |absorption |(GI, |blood-brain |barrier)
-Increased |body |fat |(keeps |fat-soluble |drugs |in |the |body |longer)
-More |sensitive |receptors
-Overall, |elderly |individuals |may |be |twice* |as |___ |to |drugs
-Common |___* |often |causes |many |drug-drug |interactions |- |CORRECT |ANSWER✔✔-50
toxic
sensitive
polypharmacy
___-___ |(T1/2): |time |required |for |the |plasma |concentration |to |decline |by |50% |after |one |dose:
-The |metabolism |rate |is |a |constant |fraction |of |the |remaining |drug, |regardless |of |many |
molecules |of |the |drug |are |metabolized
-The |body |can |increase |the |rate |(number |of |molecules |of |an |enzyme) |to |metabolize |the |
remaining |drug
-Based |on |first-order |kinetics |- |CORRECT |ANSWER✔✔-Half-life
After |1 |T1/2 |= |___% |of |drug |eliminated
Complete Solutions
___ |administration |of |a |drug:
Via |the |GI |tract
Oral |(PO)
PO |takes |about |___-___ |hours |for |75% |of |the |does |of |most |psychoactive |drugs |to |enter |the |
blood, |depending |on |lipid |(fat) |solubility |- |CORRECT |ANSWER✔✔-Enteral
1-3
___ |administration |of |a |drug:
Avoids |the |GI |tract |and |first-pass |metabolism
Inhaled
Transmucosal
Intravenous |(IV)
Intramuscular |(IM)
Transdermal |- |CORRECT |ANSWER✔✔-Parenteral
Rapid |vs. |Slow |Metabolizers:
A |second |drug |may |affect |the |metabolism |of |a |first |drug |(effect |genes/protein) |changes |
plasma/blood |level |of |the |active |(un-metabolized) |form |of |the |second |drug. |
, ___ |plasma |level |→ |SE's/toxicity. |
___ |in |plasma |level |→ |decrease |effectiveness. |- |CORRECT |ANSWER✔✔-Increase
Decrease
"Rule |of |Thumb" |for |Elderly |Doses
The |dose |is |usually |decreased |by |___%* |because:
-Decreased |hepatic |(live) |or |renal |(kidney) |function |may |cause |___ |levels
-Less |effective |barriers |to |absorption |(GI, |blood-brain |barrier)
-Increased |body |fat |(keeps |fat-soluble |drugs |in |the |body |longer)
-More |sensitive |receptors
-Overall, |elderly |individuals |may |be |twice* |as |___ |to |drugs
-Common |___* |often |causes |many |drug-drug |interactions |- |CORRECT |ANSWER✔✔-50
toxic
sensitive
polypharmacy
___-___ |(T1/2): |time |required |for |the |plasma |concentration |to |decline |by |50% |after |one |dose:
-The |metabolism |rate |is |a |constant |fraction |of |the |remaining |drug, |regardless |of |many |
molecules |of |the |drug |are |metabolized
-The |body |can |increase |the |rate |(number |of |molecules |of |an |enzyme) |to |metabolize |the |
remaining |drug
-Based |on |first-order |kinetics |- |CORRECT |ANSWER✔✔-Half-life
After |1 |T1/2 |= |___% |of |drug |eliminated